Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 1b/2 Study of HCW9218, a Bifunctional TGF ß Antagonist/IL 15 Protein Complex, for Advanced Pancreatic Cancer
NCT Number:
NCT05304936
Phase:
I/II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Pancreas
Study Objectives:
Evaluate the safety profile (as outlined by incidence of adverse events (AEs) based on CTCAE v5) of HCW9218 monotherapy in subjects with advanced/metastatic pancreatic cancer who have progressed on or are intolerant of standard first-line therapy. Determine the maximum tolerated dose (MTD) and designate the recommended Phase 2 dose level (RP2D) for Phase 2 study of HCW9218 in HCW9218-treated subjects. Evaluate the safety profile of HCW9218 in treated subjects. Determine the 6-month progression-free survival (PFS) rate of evaluable subjects treated with HCW9218.
Study Documents
(MUSC NetID required for document access)